Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05790213 · ClinicalTrials.gov registry record · Phase 2
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
A Phase 2 study of Prostate Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT05790213: Recruiting Phase 2 study of Prostate Cancer, sponsored by University of Chicago.
NCT05790213 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 57 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05790213, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Primary Outcome
Proportion of participants that have residual cancer in ablated prostate tissue. Residual disease will be measured by MRI.
Conditions Studied
Interventions
- DRUG Androgen Deprivation Therapy (ADT)
- PROCEDURE Focal prostate ablation (focal therapy)
Study Locations (1)
Illinois
- UChicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-12-18 |
| Phase | Phase 2 |
What NCT05790213 shows while recruiting
NCT05790213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Androgen Deprivation Therapy (ADT) is the first listed.
NCT05790213 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05790213 about?
NCT05790213 is a clinical study titled "Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation". The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
What is the current status of trial NCT05790213?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2025-05-05. Estimated completion is 2028-12-18.
What conditions does trial NCT05790213 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05790213?
The interventions under investigation include: Androgen Deprivation Therapy (ADT) (DRUG), Focal prostate ablation (focal therapy) (PROCEDURE).
Who is sponsoring clinical trial NCT05790213?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05790213 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05790213's enrollment target sits among peer trials
57 452nd of 735 higher than 283 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI